<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00531349</url>
  </required_header>
  <id_info>
    <org_study_id>07-532</org_study_id>
    <nct_id>NCT00531349</nct_id>
  </id_info>
  <brief_title>Regional Anesthesia and Endometrial Cancer Recurrence</brief_title>
  <acronym>ECA/R</acronym>
  <official_title>Regional Anesthesia and Endometrial Cancer Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether recurrence of local and metastatic cancer&#xD;
      after open hysterectomy for stage 1 or 2 endometrial cancer is reduced when patients receive&#xD;
      epidural anesthesia/analgesia combined with propofol sedation rather than sevoflurane&#xD;
      anesthesia and opioid analgesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III, multi-center study of patients having open hysterectomies for&#xD;
      endometrial cancer. Patients will be randomly assigned to 1) epidural anesthesia/analgesia&#xD;
      with propofol sedation; or 2) general anesthesia combined with postoperative&#xD;
      patient-controlled morphine analgesia. There will be a total (maximum) of 1700 patients&#xD;
      enrolled over a 5 year enrollment.&#xD;
&#xD;
      All patients will be premedicated with 1-3 mg IV midazolam and 1-2 µg/kg fentanyl. Patients&#xD;
      will be randomly assigned to epidural anesthesia &amp; analgesia with propofol sedation or to&#xD;
      sevoflurane general anesthesia and postoperative opioid analgesia after they have met the&#xD;
      inclusion/exclusion criteria and consent to the study.&#xD;
&#xD;
      In patients assigned to general anesthesia and opioid analgesia (General Anesthesia Group),&#xD;
      general anesthesia will be induced with 1-3 µg/kg fentanyl and 2-4 mg/kg propofol. Tracheal&#xD;
      intubation will be facilitated by succinylcholine or a non-depolarizing muscle relaxant;&#xD;
      alternatively, a supraglottic airway (such as a laryngeal mask) will be used. Additional&#xD;
      non-depolarizing muscle relaxant will be administered as deemed necessary by the attending&#xD;
      anesthesiologist.&#xD;
&#xD;
      Anesthesia will be maintained with sevoflurane in 80% oxygen, balance nitrogen, and fentanyl.&#xD;
      Sevoflurane and fentanyl administration will be adjusted to maintain blood pressure and heart&#xD;
      rate within 20% of pre-operative values. The lungs will be mechanically ventilated to&#xD;
      maintain end-tidal PCO2 near 35 mm Hg. When surgery is complete, muscle relaxant will be&#xD;
      antagonized, if necessary, and the trachea extubated. Post-operative analgesia will be&#xD;
      morphine, provided as needed IV or via patient-controlled pump. The initial pump setting will&#xD;
      be for 1 mg boluses with a 6-minute lockout period and no background infusion. Additional&#xD;
      morphine will be provided as necessary to maintain good pain control, either as needed or by&#xD;
      changing the pump settings. Morphine will be the first-line drug; but hydromorphone will be&#xD;
      substituted at one-fifth the morphine dose in patients who do not tolerate morphine. When&#xD;
      pain is adequately controlled without much morphine (usually on the second postoperative&#xD;
      day), patients will be transitioned to acetaminophen and non-steroidal anti-inflammatory&#xD;
      analgesics; oral opioids will also be permitted if necessary.&#xD;
&#xD;
      In the Epidural Anesthesia and Analgesia group, a T8-10 epidural catheter will be inserted&#xD;
      using a standard technique. After negative aspiration for blood, patients will be given a&#xD;
      test dose of 3 ml of 1.5% lidocaine and 1:200,000 epinephrine. The catheter will be&#xD;
      re-inserted or repositioned as necessary until both aspiration and test dose are negative.&#xD;
      Each patient will be given an additional 12-18 ml bolus of 0.5% bupivacaine or 0.5%&#xD;
      ropivacaine to provide intraoperative analgesia. The catheter will be repositioned or&#xD;
      reinserted as necessary if a sensory block to temperature cannot be confirmed in the surgical&#xD;
      dermatomes. Additional 5-10 ml boluses of the same solution will be given hourly during&#xD;
      surgery to maintain anesthesia; additional boluses will be permitted at the discretion of the&#xD;
      attending anesthesiologist.&#xD;
&#xD;
      Postoperative epidural analgesia will be supplemented with acetaminophen and/or NSAIDs if&#xD;
      needed, or per individual sites' routine protocol. Supplemental morphine will be provided&#xD;
      only if pain relief is inadequate, either &quot;as needed&quot; or by patient-controlled infusion. As&#xD;
      soon as practical, usually on the second postoperative day, patients will be transitioned to&#xD;
      acetaminophen and/or non-steroidal analgesics and, if necessary, oral opioids.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of study population&#xD;
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to metastatic spread or local cancer recurrence</measure>
    <time_frame>every six months throughout the study, yearly thereafter</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any-cause mortality</measure>
    <time_frame>4.4 years, 6.0 years, 7.5 years and if needed 8.9 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>General anesthesia and opioid analgesia for the treatment of pain after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regional anesthesia and analgesia (epidural) combined with deep sedation or general anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>propofol general anesthesia</intervention_name>
    <description>Regional analgesia combined with sedation or a propofol general anesthesia</description>
    <arm_group_label>B</arm_group_label>
    <other_name>propofol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>General anesthesia</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Primary endometrial cancer without known extension beyond the uterus i.e., believed to&#xD;
             be Stage 1 or 2&#xD;
&#xD;
          2. Scheduled for open abdominal hysterectomy&#xD;
&#xD;
          3. Written informed consent, including willingness to be randomized epidural&#xD;
             anesthesia/analgesia with sedation or to sevoflurane general anesthesia and&#xD;
             postoperative opioid analgesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous surgery for endometrial cancer&#xD;
&#xD;
          2. Any contraindication to epidural anesthesia or analgesia (including coagulopathy,&#xD;
             abnormal anatomy)&#xD;
&#xD;
          3. Any contraindication to midazolam, propofol, sevoflurane, fentanyl, or morphine&#xD;
&#xD;
          4. Age &lt; 18 or &gt; 85 years old&#xD;
&#xD;
          5. ASA Physical Status ≥ 4&#xD;
&#xD;
          6. Any contraindication to epidural anesthesia and analgesia (including coagulopathy,&#xD;
             abnormal anatomy)&#xD;
&#xD;
          7. Other cancer not believed by the attending surgeon to be in long-term remission&#xD;
&#xD;
          8. Systemic disease believed by the attending surgeon or anesthesiologist to present ≥&#xD;
             25% two-year mortality&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel I. Sessler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel I. Sessler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>September 17, 2007</study_first_submitted>
  <study_first_submitted_qc>September 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2007</study_first_posted>
  <last_update_submitted>May 5, 2016</last_update_submitted>
  <last_update_submitted_qc>May 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2016</last_update_posted>
  <responsible_party>
    <name_title>Daniel I. Sessler, MD</name_title>
    <organization>Cleveland Clinic</organization>
  </responsible_party>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Anesthesia; regional</keyword>
  <keyword>cancer recurrence</keyword>
  <keyword>Analgesia; opioid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

